Does cannabis cause gynaecomastia? This is a question increasingly raised by men who use cannabis and notice changes in their breast tissue. Gynaecomastia — the benign enlargement of glandular breast tissue in males — has multiple potential causes, ranging from hormonal imbalances and medications to lifestyle factors. Cannabis contains active compounds that interact with the endocannabinoid system and may theoretically influence hormone levels. However, the relationship between cannabis use and gynaecomastia is more nuanced than a simple yes or no. This article explores the current evidence, relevant mechanisms, and when to seek medical advice.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign enlargement of glandular breast tissue in males, most commonly caused by an altered oestrogen-to-testosterone ratio. Common causes include puberty, hypogonadism, liver disease, and certain medications.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular growth. The condition can affect one or both breasts and may present with tenderness, a rubbery or firm mass beneath the nipple, or visible breast enlargement. It is more common than many people realise, with estimates suggesting it affects a substantial proportion of males at some point during their lifetime — most commonly during puberty, when transient hormonal fluctuations are the most frequent cause, and again in older age.

The underlying cause is typically a hormonal imbalance — specifically, an altered ratio of oestrogen to testosterone. Oestrogen stimulates breast tissue growth, whilst testosterone normally counteracts this effect. When this balance is disrupted, glandular tissue can proliferate. Common causes include:

• Puberty — physiological gynaecomastia in adolescents usually resolves spontaneously within one to two years

• Hypogonadism — reduced testosterone production, including in Klinefelter syndrome

• Liver disease — impairs oestrogen metabolism

• Hyperthyroidism — alters sex hormone-binding globulin levels

• Chronic kidney disease — impairs hormone clearance

• Medications — including spironolactone, cimetidine, anabolic steroids, finasteride, dutasteride, bicalutamide and other anti-androgens (used in prostate cancer treatment), GnRH analogues, certain antiretrovirals (e.g. efavirenz), risperidone, ketoconazole, and some antipsychotics

• Tumours — adrenal or testicular tumours can secrete oestrogen or human chorionic gonadotrophin (hCG)

In a significant proportion of cases, no clear cause is identified, and the condition is labelled idiopathic. NICE Clinical Knowledge Summaries (CKS) on gynaecomastia recommend a thorough clinical history and examination to exclude secondary causes before attributing gynaecomastia to any single factor. Understanding the multifactorial nature of the condition is essential when evaluating the potential role of substances such as cannabis.

How Cannabis May Affect Hormone Levels in Men

THC may suppress LH secretion via the HPG axis, potentially lowering testosterone and promoting breast tissue growth, but human evidence remains inconsistent and no definitive causal pathway has been established.

Cannabis contains over 100 active compounds known as cannabinoids, the most pharmacologically significant being delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These compounds interact with the endocannabinoid system — a network of receptors (CB1 and CB2) distributed throughout the body, including in reproductive and endocrine tissues. This interaction is the basis for the theoretical link between cannabis use and hormonal disruption in men.

Research suggests that THC may interfere with the hypothalamic-pituitary-gonadal (HPG) axis, which regulates testosterone production. Animal studies have demonstrated that THC can suppress luteinising hormone (LH) secretion from the pituitary gland. Since LH stimulates the Leydig cells in the testes to produce testosterone, reduced LH levels could theoretically lead to lower circulating testosterone. A relative reduction in testosterone, even without a rise in oestrogen, may be sufficient to shift the oestrogen-to-testosterone ratio in a direction that promotes breast tissue growth. However, human studies examining the effect of cannabis on testosterone and LH have produced inconsistent results, are often short-term, and are frequently confounded by other substance use and lifestyle factors.

Additionally, some cannabinoids have been proposed to possess weak oestrogenic properties, meaning they may bind to or activate oestrogen receptors to a limited degree. However, this evidence is largely preclinical and has not been robustly demonstrated in human studies. CBD, increasingly used in isolation via legal products, has a different receptor profile to THC. Whilst CBD is not currently associated with the same HPG-axis effects as THC, human endocrine data for CBD specifically are limited, and the absence of evidence should not be interpreted as confirmed safety in this regard. The clinical significance of these mechanisms in regular cannabis users remains an area of ongoing research, and no definitive causal pathway has been established in humans to date.

For regulatory context, the UK-licensed cannabis-based medicinal products (CBMPs) Sativex (nabiximols) and Epidyolex (cannabidiol) are authorised by the MHRA; their Summary of Product Characteristics (SmPC) documents, available via the electronic Medicines Compendium (emc), and the EMA European Public Assessment Report (EPAR) for Epidyolex, provide the most current information on their known adverse effect profiles.

Evidence Linking Cannabis Use to Gynaecomastia

Current evidence suggests a possible but unconfirmed association between cannabis use and gynaecomastia; no established causal link has been confirmed in humans, and confounding factors make interpretation difficult.

The question of whether cannabis directly causes gynaecomastia in humans is not straightforwardly answered by the current evidence base. Several case reports and small observational studies have noted an association between regular cannabis use and the development of gynaecomastia in young men, but these studies are limited by small sample sizes, self-reported drug use, and the inability to control for all confounding variables.

A frequently cited concern is that many cannabis users also consume alcohol, use other recreational substances, or have lifestyle factors — such as obesity — that independently raise the risk of gynaecomastia. Disentangling the specific contribution of cannabis from these co-existing factors is methodologically challenging. Some studies have found no statistically significant association between cannabis use and gynaecomastia after adjusting for confounders.

It is important to note that no established causal link between cannabis use and gynaecomastia has been confirmed in humans. Gynaecomastia does not appear as a recognised adverse effect in the SmPCs for the UK-licensed CBMPs Sativex or Epidyolex. However, these product labels relate to specific medicinal formulations used under clinical supervision and cannot be taken to exclude the possibility of risk with recreational cannabis use, which involves different patterns of consumption, variable potency, and additional contaminants.

If you or a healthcare professional suspects that cannabis or any other substance may have contributed to a side effect, this can be reported to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

In summary, the current evidence suggests a possible but unconfirmed association. Clinicians are advised to consider cannabis use as part of a comprehensive history in men presenting with gynaecomastia, particularly younger men with no other identifiable cause, whilst avoiding attributing causation without thorough investigation.

Other Substances and Lifestyle Factors That Raise Risk

Anabolic steroids, alcohol, opioids, spironolactone, and several prescribed medications have a more firmly established link to gynaecomastia than cannabis, and obesity increases risk via peripheral aromatase activity.

When assessing gynaecomastia, it is essential to consider the broader landscape of substances and lifestyle factors that are more firmly established as contributing causes. Cannabis use rarely occurs in isolation, and several co-existing factors may be equally or more relevant.

Substances with a well-documented association with gynaecomastia include:

• Anabolic steroids — widely used in bodybuilding; they are converted peripherally to oestrogen via aromatisation

• Alcohol — chronic use impairs hepatic oestrogen metabolism and can suppress testosterone

• Opioids — suppress LH and testosterone production through central mechanisms

• Spironolactone and digoxin — prescribed medications with anti-androgenic or oestrogenic properties

• Cimetidine (an H2 receptor antagonist) — has relatively well-supported evidence for an association with gynaecomastia

• Finasteride and dutasteride (5-alpha-reductase inhibitors) — used for benign prostatic hyperplasia and hair loss

• Anti-androgens (e.g. bicalutamide) and GnRH analogues — used in prostate cancer treatment

• Certain antiretrovirals (e.g. efavirenz) and ketoconazole

• Risperidone and some other antipsychotics — via hyperprolactinaemia

• Herbal supplements — products containing lavender oil, tea tree oil, or phytoestrogens have been implicated in case reports, predominantly in younger males; the evidence is based on low-quality case series and should be interpreted cautiously

Note: proton pump inhibitors (PPIs) have been suggested as a possible cause in some reports, but the evidence is inconsistent and considerably weaker than for the agents listed above.

Lifestyle and metabolic factors also play a significant role:

• Obesity increases peripheral conversion of androgens to oestrogens via aromatase activity in adipose tissue

• Malnutrition or refeeding can transiently alter hormone levels

• Chronic kidney disease and liver cirrhosis impair hormone clearance

A thorough medication and substance use history — including prescribed medicines, over-the-counter products, supplements, and recreational drugs — is a cornerstone of the clinical assessment recommended by NICE CKS. The BNF provides further detail on drug-induced gynaecomastia. Identifying and addressing modifiable risk factors, such as reducing alcohol intake or discontinuing a causative medication under medical supervision, is often the first step in management.

When to See a GP About Breast Tissue Changes

Men should contact their GP promptly if they notice a new breast lump, rapid enlargement, nipple discharge, or skin changes; NICE NG12 recommends urgent two-week wait referral for men aged 30 and over with an unexplained breast lump.

Many men feel embarrassed or uncertain about seeking medical advice for breast changes, but prompt assessment is important to exclude serious underlying causes. Whilst the majority of gynaecomastia cases are benign, some presentations warrant urgent investigation.

You should contact your GP if you notice:

• A new lump or swelling in one or both breasts

• Breast tissue that is tender, painful, or rapidly enlarging

• Nipple discharge, particularly if bloodstained

• Skin changes over the breast, such as dimpling, puckering, or redness

• Associated symptoms such as testicular pain or swelling, unexplained weight loss, or fatigue

Male breast cancer, whilst rare — accounting for less than 1% of all breast cancer cases in the UK — can present similarly to gynaecomastia. Key distinguishing features include eccentric positioning of the lump (away from the nipple), hard or irregular texture, and associated lymphadenopathy. In line with NICE NG12 (Suspected cancer: recognition and referral), GPs should refer men aged 30 and over with an unexplained breast lump urgently via the two-week wait pathway. Men aged 50 and over with unilateral nipple changes (such as discharge, retraction, or other concerning changes) or skin changes suggesting breast cancer should also be referred urgently. Local pathways may apply for men under 30 presenting with a breast lump.

For men who use cannabis regularly and develop breast changes, it is advisable to disclose this to their GP without concern about judgement. A full clinical history, including all substance use, enables the most accurate assessment. The GP may arrange blood tests — including early morning total testosterone, LH, follicle-stimulating hormone (FSH), oestradiol, prolactin, beta-hCG, thyroid function tests (TFTs), liver function tests (LFTs), and renal function — alongside testicular examination and ultrasound if examination findings or laboratory results suggest a testicular source. Early assessment not only provides reassurance but ensures that any treatable underlying cause is identified promptly. Further guidance is available via NICE CKS on gynaecomastia and the NHS page on breast cancer in men.

Treatment and Management Options Available on the NHS

NHS management of gynaecomastia focuses first on addressing the underlying cause; pharmacological options such as tamoxifen are most effective within the first six to twelve months, and surgical treatment is available in cases of significant distress subject to local commissioning.

The management of gynaecomastia on the NHS depends on the underlying cause, the duration of the condition, the degree of distress it causes, and whether it is likely to resolve spontaneously. In many cases — particularly in adolescents — watchful waiting is appropriate, as physiological gynaecomastia often resolves within one to two years without intervention.

Where a causative factor is identified, addressing it is the primary treatment strategy:

• Discontinuing or substituting a causative medication (under medical supervision)

• Treating an underlying condition such as hypogonadism, hyperthyroidism, or a prolactinoma

• Reducing or stopping alcohol or recreational drug use, including cannabis

• Weight management in cases where obesity is a contributing factor

Pharmacological treatment is not routinely commissioned across all NHS organisations for gynaecomastia, and availability varies by Integrated Care Board (ICB) or health board. Where it is considered, it is most effective when initiated within the first six to twelve months of onset, whilst the breast tissue remains in the active, proliferative phase and before fibrosis develops. Options used off-label include tamoxifen (a selective oestrogen receptor modulator, or SERM), which may benefit selected cases and should be initiated by a specialist rather than in primary care. Aromatase inhibitors such as anastrozole have limited evidence in adult men and are not generally recommended as routine treatment according to the European Society of Endocrinology (ESE) Clinical Practice Guideline on gynaecomastia (2019).

Surgical treatment — subcutaneous mastectomy or liposuction — may be available on the NHS in cases where gynaecomastia causes significant psychological distress or functional impairment, though access varies by NHS organisation and is subject to individual funding request processes. Referral to endocrinology is appropriate when the underlying cause is uncertain or an endocrine disorder is suspected; referral to general surgery is appropriate when gynaecomastia is persistent, fibrotic, or significantly distressing after conservative measures have been tried. NICE CKS on gynaecomastia and the NHS patient information page on enlarged male breasts provide further guidance. Men are encouraged to discuss all available options openly with their GP to determine the most suitable pathway for their individual circumstances.

Frequently Asked Questions